$DVA
DAVITA INC.

2014 Form 10-K Financial Statement

#000156459015001035 Filed on February 26, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013 Q3
Revenue $12.80B $3.063B $3.000B
YoY Change 8.76% 23.62% 54.15%
Cost Of Revenue $9.119B $2.128B $2.095B
YoY Change 11.23% 24.61% 57.85%
Gross Profit $3.676B $935.4M $904.3M
YoY Change 3.08% 21.42% 46.21%
Gross Profit Margin 28.73% 30.54% 30.15%
Selling, General & Admin $1.276B $320.0M $306.6M
YoY Change 8.04% 16.53% 53.84%
% of Gross Profit 34.71% 34.21% 33.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $428.3M $138.7M $132.8M
YoY Change 14.8% 26.67% 64.72%
% of Gross Profit 11.65% 14.83% 14.68%
Operating Expenses $1.867B $459.5M $439.4M
YoY Change 9.12% 19.69% 57.27%
Operating Profit $1.815B $484.2M $377.1M
YoY Change 17.1% 24.77% 10.62%
Interest Expense -$485.0M -$99.30M -$99.20M
YoY Change 22.78% 0.51% 47.18%
% of Operating Profit -26.72% -20.51% -26.31%
Other Income/Expense, Net $2.374M $3.500M $2.113M
YoY Change -50.41% 250.0% 158.0%
Pretax Income $1.341B $380.0M $270.8M
YoY Change 19.22% 34.68% -0.16%
Income Tax $446.3M $135.7M $100.9M
% Of Pretax Income 33.28% 35.71% 37.28%
Net Earnings $723.1M $212.3M $136.6M
YoY Change 14.16% 36.22% -5.59%
Net Earnings / Revenue 5.65% 6.93% 4.55%
Basic Earnings Per Share $3.41 $1.01 $0.65
Diluted Earnings Per Share $3.33 $0.99 $0.64
COMMON SHARES
Basic Shares Outstanding 212.3M 212.7M shares 210.4M shares
Diluted Shares Outstanding 216.9M 214.9M shares

Balance Sheet

Concept 2014 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.303B $971.3M $977.0M
YoY Change 36.73% 79.53% 151.8%
Cash & Equivalents $965.0M $946.2M $970.7M
Short-Term Investments $337.0M $25.02M $7.000M
Other Short-Term Assets $186.0M $176.4M $156.9M
YoY Change -68.26% -12.48% 233.99%
Inventory $136.0M $88.81M $84.90M
Prepaid Expenses $93.88M
Receivables $1.526B $1.485B $1.404B
Other Receivables $485.0M $349.1M $360.0M
Total Short-Term Assets $3.636B $3.472B $3.381B
YoY Change 4.72% 20.27% 45.39%
LONG-TERM ASSETS
Property, Plant & Equipment $2.469B $2.189B $2.048B
YoY Change 12.79% 16.93% 23.79%
Goodwill $9.213B $9.144B
YoY Change 2.91% 71.72%
Intangibles $2.024B $2.060B
YoY Change -4.87% 1060.05%
Long-Term Investments $155.0M $120.0M $114.0M
YoY Change 29.17% 27.66% 171.43%
Other Assets $77.00M $79.60M $79.83M
YoY Change -3.75% -0.32% 161.25%
Total Long-Term Assets $13.98B $13.63B $13.45B
YoY Change 2.6% 3.8% 58.22%
TOTAL ASSETS
Total Short-Term Assets $3.636B $3.472B $3.381B
Total Long-Term Assets $13.98B $13.63B $13.45B
Total Assets $17.62B $17.10B $16.83B
YoY Change 3.03% 6.77% 55.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $445.0M $435.5M $358.4M
YoY Change 2.3% 5.15% 31.46%
Accrued Expenses $1.169B $772.0M $685.0M
YoY Change 14.16% 36.16% 29.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $120.0M $274.7M $260.0M
YoY Change -56.36% 20.48% 120.67%
Total Short-Term Liabilities $2.089B $2.462B $2.453B
YoY Change -15.15% 22.1% 83.5%
LONG-TERM LIABILITIES
Long-Term Debt $8.299B $8.141B $8.181B
YoY Change 1.94% -2.23% 45.55%
Other Long-Term Liabilities $390.0M $380.3M $353.7M
YoY Change 2.63% -14.29% 143.53%
Total Long-Term Liabilities $8.689B $380.3M $353.7M
YoY Change 1.97% -14.29% -93.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.089B $2.462B $2.453B
Total Long-Term Liabilities $8.689B $380.3M $353.7M
Total Liabilities $12.45B $11.80B $11.77B
YoY Change -1.73% 2.42% 54.78%
SHAREHOLDERS EQUITY
Retained Earnings $3.364B $3.152B
YoY Change -9.86% -11.86%
Common Stock $213.0K $213.0K
YoY Change -21.11% 57.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 0.000 shares
Shareholders Equity $5.171B $4.432B $4.268B
YoY Change
Total Liabilities & Shareholders Equity $17.62B $17.10B $16.83B
YoY Change 3.03% 6.77% 55.46%

Cashflow Statement

Concept 2014 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income $723.1M $212.3M $136.6M
YoY Change 14.16% 36.22% -5.59%
Depreciation, Depletion And Amortization $428.3M $138.7M $132.8M
YoY Change 14.8% 26.67% 64.72%
Cash From Operating Activities $1.459B $354.1M $733.2M
YoY Change -17.7% 76.87% 100.0%
INVESTING ACTIVITIES
Capital Expenditures $641.3M -$218.1M -$141.1M
YoY Change 3.84% 27.39% 9.89%
Acquisitions
YoY Change
Other Investing Activities -$636.4M -$81.70M -$88.10M
YoY Change 145.43% -97.89% 23.91%
Cash From Investing Activities -$1.278B -$299.8M -$229.2M
YoY Change 45.71% -92.59% 14.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -165.0M -78.80M -150.5M
YoY Change -65.84% -101.97% 157.26%
NET CHANGE
Cash From Operating Activities 1.459B 354.1M 733.2M
Cash From Investing Activities -1.278B -299.8M -229.2M
Cash From Financing Activities -165.0M -78.80M -150.5M
Net Change In Cash 16.70M -24.50M 353.5M
YoY Change -95.96% -116.08% 225.81%
FREE CASH FLOW
Cash From Operating Activities $1.459B $354.1M $733.2M
Capital Expenditures $641.3M -$218.1M -$141.1M
Free Cash Flow $818.1M $572.2M $874.3M
YoY Change -29.22% 54.07% 76.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
215800000
CY2012 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-10130000
CY2013 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
169000
CY2014 dva Patient Care Costs
PatientCareCosts
9119305000
CY2014 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
12795106000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1176485000
CY2012 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
8186280000
CY2013 dva Patient Care Costs
PatientCareCosts
8198377000
CY2012 dva Patient Care Costs
PatientCareCosts
5583549000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
536017000
CY2014 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
3.41
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-12889000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2300000
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1541000
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
490000
CY2012 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
75000
CY2013 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.95
CY2012 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.79
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.02
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2015Q1 dei Entity Public Float
EntityPublicFloat
16200000000
CY2012 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
7351902000
CY2012 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
235218000
CY2012 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
7116684000
CY2012 us-gaap Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
481336000
CY2012 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-222000
CY2013 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
13375000
CY2012 us-gaap Profit Loss
ProfitLoss
641237000
CY2012 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
105220000
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.79
CY2014 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
3.33
CY2012 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.74
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.74
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212301827
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
192035878
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
195942160
CY2012 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
536236000
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
13249000
CY2012 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-219000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2216000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1205000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12652000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4187000
CY2014 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
840958000
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
769853000
CY2012 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
645424000
CY2013 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
123755000
CY2012 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
105220000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
646098000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
540204000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
965241000
CY2014 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
8501454000
CY2014 us-gaap Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
1032364000
CY2013 us-gaap Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
2987315000
CY2014 us-gaap Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
3261288000
CY2013 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
11764050000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1261506000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
14453000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
889879000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
590935000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
341969000
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4852000
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4339000
CY2014 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
23234000
CY2013 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
34558000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
10213916000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
6889196000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
1550134000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
1297084000
CY2013 us-gaap Interest And Debt Expense
InterestAndDebtExpense
429943000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1124978000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1001304000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
381013000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
359845000
CY2012 us-gaap Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
588260000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
528737000
CY2012 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
16377000
CY2012 us-gaap Interest And Debt Expense
InterestAndDebtExpense
288554000
CY2012 dva Debt Refinancing Charge
DebtRefinancingCharge
10963000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4787000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3737000
CY2012 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-6204000
CY2012 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
641459000
CY2013 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-139000
CY2014 us-gaap Profit Loss
ProfitLoss
863330000
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
214800000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
15500000000
CY2014 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
8868338000
CY2013 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
8307195000
CY2014 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
366884000
CY2013 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
293546000
CY2013 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
8013649000
CY2013 us-gaap Health Care Organization Other Revenue
HealthCareOrganizationOtherRevenue
763086000
CY2014 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
17000000
CY2013 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
397000000
CY2012 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
85837000
CY2013 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-56977000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
10979965000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1815141000
CY2014 us-gaap Interest And Debt Expense
InterestAndDebtExpense
410294000
CY2014 dva Debt Refinancing Charge
DebtRefinancingCharge
97548000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2374000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1309673000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
446343000
CY2014 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
863330000
CY2013 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
743965000
CY2013 us-gaap Profit Loss
ProfitLoss
757201000
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
140216000
CY2013 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
123755000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
723114000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
633446000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.41
CY2013 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.89
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.33
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.95
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
209939364
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
216927681
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214763887
CY2014 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
723114000
CY2013 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
620197000
CY2014 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-10059000
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-10608000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
238000
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
207000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22952000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22372000
CY2014 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
140216000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
700742000
CY2014 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
83590000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
40878000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
38368000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
18476000
CY2013 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
78817000
CY2014 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-60475000
CY2013 dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
108434000
CY2012 dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-51730000
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2916000
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-17731000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4052000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2956000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
946249000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
337399000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
6801000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1525849000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1485163000
CY2014Q4 us-gaap Inventory Net
InventoryNet
136085000
CY2013Q4 us-gaap Inventory Net
InventoryNet
88805000
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
400916000
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
349090000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
186842000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
176414000
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83839000
CY2013Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
10315000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
240626000
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
409441000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
3876797000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
3472278000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2469099000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2189411000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1949498000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2024373000
CY2014Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
65637000
CY2013Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
40686000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
89389000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
79557000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
77000000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79598000
CY2014Q4 us-gaap Goodwill
Goodwill
9415295000
CY2013Q4 us-gaap Goodwill
Goodwill
9212974000
CY2014Q4 us-gaap Assets
Assets
17942715000
CY2013Q4 us-gaap Assets
Assets
17098877000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
445453000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
435465000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
506579000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
464422000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
698475000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
603013000
CY2014Q4 dva Medical Expense Payable
MedicalExpensePayable
314347000
CY2013Q4 dva Medical Expense Payable
MedicalExpensePayable
287452000
CY2014Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
3644000
CY2013Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
397000000
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
120154000
CY2013Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
274697000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2088652000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2462049000
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8383280000
CY2013Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8141231000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
389806000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
380337000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
890701000
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
812419000
CY2014Q4 us-gaap Liabilities
Liabilities
11752439000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
213000
CY2013Q4 us-gaap Liabilities
Liabilities
11796036000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
829965000
CY2013Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
697300000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
216000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1108211000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1070922000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4087103000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3363989000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25017000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2645000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
5170513000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4432479000
CY2014Q4 us-gaap Minority Interest
MinorityInterest
189798000
CY2013Q4 us-gaap Minority Interest
MinorityInterest
173062000
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5360311000
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4605541000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17942715000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17098877000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
242674000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
237143000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
215640968
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
213163248
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
215640968
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
213163248
CY2014 us-gaap Loss Contingency Accrual Carrying Value Period Increase Decrease
LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
17000000
CY2013 us-gaap Loss Contingency Accrual Carrying Value Period Increase Decrease
LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
397000000
CY2014 dva Adjustment Depreciation And Amortization
AdjustmentDepreciationAndAmortization
590935000
CY2013 dva Adjustment Depreciation And Amortization
AdjustmentDepreciationAndAmortization
528119000
CY2012 dva Adjustment Depreciation And Amortization
AdjustmentDepreciationAndAmortization
343908000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
56743000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
59998000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
45384000
CY2014 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
59119000
CY2013 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
46898000
CY2012 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
88964000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
45271000
CY2013 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
36197000
CY2012 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
62036000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
60538000
CY2014 dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-10125000
CY2013 dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-2872000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
8440000
CY2012 dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-3384000
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
12445000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-25380000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
43765000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
210955000
CY2014 dva Gain Loss On Disposal Of Assets And Other Noncash Charges
GainLossOnDisposalOfAssetsAndOtherNoncashCharges
39274000
CY2013 dva Gain Loss On Disposal Of Assets And Other Noncash Charges
GainLossOnDisposalOfAssetsAndOtherNoncashCharges
-31351000
CY2012 dva Gain Loss On Disposal Of Assets And Other Noncash Charges
GainLossOnDisposalOfAssetsAndOtherNoncashCharges
30390000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
40676000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
59640000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47673000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
46398000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8971000
CY2014 dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
61674000
CY2012 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1775000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16666000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
97261000
CY2012 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
11083000
CY2014 dva Increase Decrease In Loss Contingency Reserve
IncreaseDecreaseInLossContingencyReserve
-410356000
CY2013 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
33499000
CY2012 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-129948000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1583000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
66145000
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
19029000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1459407000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1773341000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1100848000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
641330000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
617597000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
550146000
CY2014 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
272094000
CY2013 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
310394000
CY2012 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
4294077000
CY2014 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
8791000
CY2013 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
62258000
CY2012 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3559000
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3935000
CY2014 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
472628000
CY2013 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
1039000
CY2012 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
7418000
CY2014 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2475000
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
4158000
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
7211000
CY2014 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
141072000
CY2013 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
1376000
CY2012 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
14530000
CY2014 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1018000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2391000
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
830000
CY2014 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
35382000
CY2013 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
1305000
CY2012 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
1352000
CY2014 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
825000
CY2012 dva Weighted Average Number Basic Shares Outstanding Adjustment
WeightedAverageNumberBasicSharesOutstandingAdjustment
192396000
CY2013 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
2194000
CY2012 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
366000
CY2013 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
633446000
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2631000
CY2012 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3540000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4194000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2616000
CY2013Q4 dva Percentage Of Accounts Receivable Six Months Or More Past Due
PercentageOfAccountsReceivableSixMonthsOrMorePastDue
0.14
CY2013 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
-7979000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93877000
CY2014Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3100000
CY2013Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3220000
CY2014Q4 us-gaap Land
Land
35885000
CY2013 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
497000
CY2012 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
8000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1277729000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-876882000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
393752000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4832450000
CY2014 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
60038508000
CY2013 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
66286097000
CY2012 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
43248175000
CY2014 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
60046487000
CY2013 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
66723385000
CY2012 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
39286027000
CY2014 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
122988000
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
719000
CY2012 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
57241000
CY2014 dva Payments Of Distributions Return Of Capital
PaymentsOfDistributionsReturnOfCapital
149339000
CY2013 dva Payments Of Distributions Return Of Capital
PaymentsOfDistributionsReturnOfCapital
139326000
CY2012 dva Payments Of Distributions Return Of Capital
PaymentsOfDistributionsReturnOfCapital
113504000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19500000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16423000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6647000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
45271000
CY2013 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
36197000
CY2012 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
62036000
CY2014 dva Contribution From Noncontrolling Interest
ContributionFromNoncontrollingInterest
64655000
CY2013 dva Contribution From Noncontrolling Interest
ContributionFromNoncontrollingInterest
36996000
CY2012 dva Contribution From Noncontrolling Interest
ContributionFromNoncontrollingInterest
37395000
CY2014 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
3777000
CY2013 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
8295000
CY2012 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1664000
CY2014 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
17876000
CY2013 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
3569000
CY2012 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
26761000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-164979000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-482991000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3872384000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2293000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-967000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-786000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18992000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
412501000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
139996000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
533748000
CY2014Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
157550000
CY2013Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
157998000
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
2002735000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1762470000
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2066775000
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1839981000
CY2014Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
235660000
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
172261000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4498605000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3967670000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2029506000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1778259000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
428309000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
373107000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
299810000
CY2014 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
7888000
CY2013 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
6408000
CY2012 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
8126000
CY2014Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
1575865000
CY2014Q4 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
171168000
CY2013Q4 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
170994000
CY2014Q4 dva Provider Network And Practice Management Tools Gross
ProviderNetworkAndPracticeManagementToolsGross
183688000
CY2013Q4 dva Provider Network And Practice Management Tools Gross
ProviderNetworkAndPracticeManagementToolsGross
184558000
CY2014Q4 us-gaap Finite Lived Noncompete Agreements Gross
FiniteLivedNoncompeteAgreementsGross
506867000
CY2013Q4 us-gaap Finite Lived Noncompete Agreements Gross
FiniteLivedNoncompeteAgreementsGross
495475000
CY2014Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
2571389000
CY2013Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
2508146000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
483773000
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
47489000
CY2012 dva Amortization Of Intangible Assets And Liabilities Net
AmortizationOfIntangibleAssetsAndLiabilitiesNet
103000
CY2013Q4 dva Intangible Lease Liabilities
IntangibleLeaseLiabilities
12563000
CY2013Q4 dva Finite Lived Intangible Liabilities Net
FiniteLivedIntangibleLiabilitiesNet
21890000
CY2013Q4 dva Intangible Lease Liabilities Accumulated Amortization
IntangibleLeaseLiabilitiesAccumulatedAmortization
2628000
CY2012 dva Amortization Expense Benefit From Alliance And Product Supply Agreement
AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement
5330000
CY2014 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the Company&#8217;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#8217;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#8217;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inquiries by the Federal Government and Certain Related Civil Proceedings </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vainer Private Civil Suit</font>: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for HHS relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company was advised by the U.S. Attorney&#8217;s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC that this was a civil inquiry. On June&#160;17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act. On April&#160;1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney&#8217;s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators&#8217; allegation in litigation. On July&#160;25, 2011, the relators, Daniel Barbir and Dr.&#160;Alon Vainer, filed their amended civil complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The amended complaint alleges that the Company&#8217;s drug administration practices for the Company&#8217;s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. The amended complaint seeks monetary damages and civil penalties as well as costs and expenses. The parties completed discovery in early 2014; however in August 2014, the Court granted relators&#8217; motion for sanctions and reopened discovery on a limited basis. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation. The Company cannot predict the ultimate outcome of this case, but if the case is resolved in favor of the plaintiffs, its resolution could have a material adverse effect on our earnings and cash flows. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2010 U.S. Attorney Physician Relationship Investigation</font>: As previously disclosed, the U.S. Attorney&#8217;s Office for the District of Colorado and the OIG investigated, among other things, the Company&#8217;s financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. This investigation has been described in the Company&#8217;s prior Reports on Forms 10-K and 10-Q and referred to as the 2010 U.S. Attorney Physician Relationship Investigation. This investigation overlapped substantially with the investigation described below under the caption 2011 U.S. Attorney Physician Relationship Investigation. The Company disclosed in early 2014 that it had reached an agreement in principle with the government to resolve these matters. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described more fully in the Company&#8217;s current report on Form 8-K filed on October 23, 2014, and as also disclosed in the Company&#8217;s prior report on Form 10-Q for the quarter ended September 30, 2014 that was filed with the SEC on November 6, 2014, the Company entered into a final settlement agreement on October&#160;22, 2014 (the Settlement Agreement) with the United States of America, acting through the United States Department of Justice and on behalf of the OIG, the Defense Health Agency on behalf of TRICARE, through its General Counsel (collectively, the United States) and relator David Barbetta, to resolve the 2010 and 2011 U.S. Attorney Physician Relationship Investigations. In connection with the resolution of these matters, the Company agreed to pay and has now paid to the United States $350,000 plus accrued interest from the date of the Company&#8217;s agreement in principle with the United States, plus a civil forfeiture of $39,000. In addition, the Company agreed to and has paid a settlement of certain state Medicaid claims in the amount of $11,500 plus interest. Under the Settlement Agreement, among other things, the United States agrees to release the Company from any civil or administrative monetary liability arising from allegations that the Company caused the submission of claims to the federal health care programs that were ineligible for reimbursement due to certain violations of the federal anti-kickback statute in connection with certain of its dialysis center joint venture arrangements, and the United States and the relator agree to dismissal of the civil action filed by the relator under the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act. The Company also has entered into a five-year corporate integrity agreement (the CIA) with the OIG. The CIA, among other things, (i)&#160;requires that the Company maintain certain elements of its compliance programs, (ii)&#160;imposes certain expanded compliance-related requirements during the term of the CIA, (iii)&#160;requires ongoing monitoring, reporting, certification, records retention and training obligations, the formal allocation of certain oversight responsibility to the Board&#8217;s Compliance Committee, the creation of a Management Compliance Committee and the retention of an independent compliance advisor to the Board, and (iv)&#160;contains certain business restrictions related to a subset of the Company&#8217;s joint venture arrangements, including the Company&#8217;s agreeing to: (1)&#160;unwind 11 joint venture transactions that were created through partial divestitures to or partial acquisitions from nephrologists and that cover 26 of the Company&#8217;s 2,119 clinics that existed at the time the Company entered into the Settlement Agreement; (2)&#160;not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the CIA; and (3)&#160;certain other restrictions. In the event of a breach of the CIA, the Company could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The costs associated with compliance with the CIA could be substantial and may be greater than the Company currently anticipates. In 2013, the Company accrued a loss contingency reserve of $397,000 related to this matter. In the third quarter of 2014, the Company accrued an additional $17,000 related to this matter which resulted in an increase in the reserve from $397,000 to $414,000.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Physician Relationship Investigation</font>: In August 2011, the Company announced it had learned that the U.S. Attorney&#8217;s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation related to the Company&#8217;s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlapped substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As also described above, both the 2010 and 2011 U.S. Attorney Physician Relationship Investigations have now been resolved. The United States has informed the Company that it has declined to proceed with any criminal charges in connection with this matter. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company&#8217;s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney&#8217;s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company&#8217;s understanding that this inquiry is civil in nature. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle to resolve this matter. The specific terms of a settlement have not been finalized. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Swoben Private Civil Suit</font>:&#160;In April 2013, the Company&#8217;s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July&#160;13, 2009, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a <font style="font-style:italic;">qui tam</font> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN.&#160;In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations&#160;of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores.&#160;The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June&#160;26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July&#160;30, 2013, the court granted HCP&#8217;s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare&#160;&amp; Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court&#8217;s disposition of the appeal is pending. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font>: In February 2015, the Company announced that it received six subpoenas from the OIG&#160;for medical records from six different dialysis centers in Southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of the respective dialysis center. The Company has been advised by an attorney with the Civil Division of the United States Attorney&#8217;s Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation.&#160; The Company does not provide transportation or bill for the transport of its dialysis patients.&#160; The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the private civil complaints filed by the relators as described above, to the Company&#8217;s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management&#8217;s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators&#8217; claims (except as described above), or the potential range of damages, if any. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shareholder Derivative Claims </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">In re DaVita HealthCare Partners Inc. Derivative Litigation</font>: On January&#160;7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May&#160;17, 2013 and the Clark Shareholder action filed on August&#160;7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company&#8217;s directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. The Company has entered into a settlement with the lead plaintiff, subject to court approval. The terms of the settlement, which were described in a court-ordered notice sent to shareholders in late January 2015, include enhancements to the Company&#8217;s corporate governance practices and provides that the Company will not oppose the derivative plaintiff&#8217;s application for an award of fees and expenses, the dollar amount of which is not material to the Company. On January 8, 2015, the Court entered an order preliminarily approving the settlement, directing that the notice to shareholders be provided as described above and setting a settlement fairness hearing on May 1, 2015.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs&#8217; motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court&#8217;s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company&#8217;s consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company&#8217;s consolidated financial statements. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows. </p></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets including goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements. </p></div>
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2432000
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.06
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
633446000
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2014 dva Ownership In Joint Venture
OwnershipInJointVenture
0.50
CY2014Q4 dva Number Of Entities That Third Parties Held Non Controlling Ownership
NumberOfEntitiesThatThirdPartiesHeldNonControllingOwnership
380
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
723114000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
536017000
CY2014 dva Weighted Average Number Basic Shares Outstanding Adjustment
WeightedAverageNumberBasicSharesOutstandingAdjustment
214496000
CY2013 dva Weighted Average Number Basic Shares Outstanding Adjustment
WeightedAverageNumberBasicSharesOutstandingAdjustment
212128000
CY2013 dva Stock Issued Or Vested During Period Shares Stock Awards
StockIssuedOrVestedDuringPeriodSharesStockAwards
5000
CY2012 dva Stock Issued Or Vested During Period Shares Stock Awards
StockIssuedOrVestedDuringPeriodSharesStockAwards
6000
CY2014 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
2194000
CY2013 dva Income Loss From Discontinued Operations Per Basic Share
IncomeLossFromDiscontinuedOperationsPerBasicShare
0.07
CY2014 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
723114000
CY2012 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
536017000
CY2014Q4 dva Percentage Of Outstanding Patient Accounts Receivables
PercentageOfOutstandingPatientAccountsReceivables
1.00
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6801000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1715000
CY2014Q4 dva Percentage Of Accounts Receivable Six Months Or More Past Due
PercentageOfAccountsReceivableSixMonthsOrMorePastDue
0.12
CY2014 dva Accounts Receivable Period Outstanding
AccountsReceivablePeriodOutstanding
P4M
CY2014 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
5531000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
102466000
CY2014Q4 us-gaap Deposit Assets
DepositAssets
81276000
CY2013Q4 us-gaap Deposit Assets
DepositAssets
79317000
CY2013Q4 us-gaap Land
Land
34960000
CY2013Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
1503426000
CY2014Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
101001000
CY2013Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
121872000
CY2014Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
24818000
CY2013Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
22932000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
621891000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167956000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
160960000
CY2014 dva Amortization Of Intangible Assets And Liabilities Net
AmortizationOfIntangibleAssetsAndLiabilitiesNet
-1798000
CY2013 dva Amortization Of Intangible Assets And Liabilities Net
AmortizationOfIntangibleAssetsAndLiabilitiesNet
-1447000
CY2014Q4 dva Alliance And Product Supply Agreement Gross
AllianceAndProductSupplyAgreementGross
68200000
CY2013Q4 dva Alliance And Product Supply Agreement Gross
AllianceAndProductSupplyAgreementGross
68200000
CY2014Q4 dva Amortized Intangible Liabilities Accumulated Amortization
AmortizedIntangibleLiabilitiesAccumulatedAmortization
64203000
CY2013Q4 dva Amortized Intangible Liabilities Accumulated Amortization
AmortizedIntangibleLiabilitiesAccumulatedAmortization
58873000
CY2014Q4 dva Product Supply Agreement
ProductSupplyAgreement
3997000
CY2013Q4 dva Product Supply Agreement
ProductSupplyAgreement
9327000
CY2014Q4 dva Intangible Lease Liabilities
IntangibleLeaseLiabilities
10407000
CY2014Q4 dva Finite Lived Intangible Liabilities Net
FiniteLivedIntangibleLiabilitiesNet
14404000
CY2014Q4 dva Intangible Lease Liabilities Accumulated Amortization
IntangibleLeaseLiabilitiesAccumulatedAmortization
4785000
CY2014 dva Amortization Expense Benefit From Alliance And Product Supply Agreement
AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement
5330000
CY2013 dva Amortization Expense Benefit From Alliance And Product Supply Agreement
AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement
5330000
CY2014Q4 dva Certificates Of Deposit Money Market Funds And United States Government Securities
CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities
335975000
CY2013Q4 dva Certificates Of Deposit Money Market Funds And United States Government Securities
CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities
5601000
CY2014Q4 dva Mutual Fund Investments At Fair Value
MutualFundInvestmentsAtFairValue
28123000
CY2013Q4 dva Mutual Fund Investments At Fair Value
MutualFundInvestmentsAtFairValue
19421000
CY2014Q4 us-gaap Marketable Securities
MarketableSecurities
364098000
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
25022000
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
337399000
CY2014Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26699000
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
18221000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
5181000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
5096000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
425000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3752000
CY2014 dva Proceeds From Sale Of Available For Sale Securities Previously Recorded In Oci
ProceedsFromSaleOfAvailableForSaleSecuritiesPreviouslyRecordedInOCI
1262000
CY2013 dva Proceeds From Sale Of Available For Sale Securities Previously Recorded In Oci
ProceedsFromSaleOfAvailableForSaleSecuritiesPreviouslyRecordedInOCI
4158000
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
340000
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
802000
CY2012Q4 us-gaap Goodwill
Goodwill
8952750000
CY2013 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
271267000
CY2013 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
2728000
CY2013 us-gaap Goodwill Other Changes
GoodwillOtherChanges
8315000
CY2014 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
221514000
CY2014 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
1851000
CY2013 dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
11149000
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
2077000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
186000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
68715000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
49178000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1687000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1764000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
660000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
220778000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
404737000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
289070000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
192267000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6695000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2014 us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
17342000
CY2014 us-gaap Goodwill Impaired Change In Estimate Description
GoodwillImpairedChangeInEstimateDescription
For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 2.5%, 2.8% and 3.0%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 5.3%, 5.9% and 6.3%, respectively.
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2014Q4 us-gaap Customer Advances And Deposits Current
CustomerAdvancesAndDepositsCurrent
125435000
CY2013Q4 us-gaap Customer Advances And Deposits Current
CustomerAdvancesAndDepositsCurrent
169480000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
15614000
CY2013Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
6577000
CY2014Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
92928000
CY2013Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
84882000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
87224000
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
45662000
CY2014Q4 dva Accrued Medical Claims Current
AccruedMedicalClaimsCurrent
39867000
CY2013Q4 dva Accrued Medical Claims Current
AccruedMedicalClaimsCurrent
31219000
CY2014Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
25909000
CY2013Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
18366000
CY2014Q4 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
1457000
CY2013Q4 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
12069000
CY2014Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
118145000
CY2013Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
96167000
CY2014 dva Increase Decrease In Prior Year Estimates Of Health Care Costs Payable
IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable
3429000
CY2013 dva Increase Decrease In Prior Year Estimates Of Health Care Costs Payable
IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable
-16587000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
188302000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
334258000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
239232000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
30789000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
64195000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
32360000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-8941000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
6498000
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
938000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
746000
CY2014 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
225565000
CY2013 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-14890000
CY2012 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
70693000
CY2014 dva Income Tax Expense Benefit Continuing Operations And Discontinued Operations
IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations
446343000
CY2013 dva Income Tax Expense Benefit Continuing Operations And Discontinued Operations
IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations
389847000
CY2012 dva Income Tax Expense Benefit Continuing Operations And Discontinued Operations
IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations
359763000
CY2013 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
-84000
CY2012 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
-82000
CY2013 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
8918000
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2013 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.006
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.003
CY2013 dva Effective Income Tax Rate Reconciliation Contingent Earn Out Adjustments
EffectiveIncomeTaxRateReconciliationContingentEarnOutAdjustments
-0.026
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.014
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.011
CY2014 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.040
CY2013 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.041
CY2012 us-gaap Effective Income Tax Rate Reconciliation Minority Interest Income Expense
EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
-0.042
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.341
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.339
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.359
CY2014Q4 dva Deferred Tax Assets Receivables
DeferredTaxAssetsReceivables
42973000
CY2013Q4 dva Deferred Tax Assets Receivables
DeferredTaxAssetsReceivables
49667000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
253158000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
252008000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
1423000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
139844000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
100768000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
96212000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
88435000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
67882000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
486757000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
605613000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26667000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13860000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
460090000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
591753000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
835816000
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
752838000
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
187054000
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
183059000
CY2014Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
78618000
CY2013Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
51921000
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
8677000
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6913000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1110165000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
994731000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-650075000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-402978000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12807000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
914000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
27312000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
31877000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
67546000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6005000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3901000
CY2014 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-5002000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
262645000
CY2013 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-4561000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
424096000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
901792000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
302752000
CY2013 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
8480000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
632000
CY2014 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
28661000
CY2014Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
27427000
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
10123000
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
10742000
CY2014Q4 us-gaap Senior Notes
SeniorNotes
3775000000
CY2013Q4 us-gaap Senior Notes
SeniorNotes
2800000000
CY2014Q4 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
69045000
CY2013Q4 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
67352000
CY2014Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
218097000
CY2013Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
152751000
CY2014Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8519642000
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8433603000
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
16208000
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
17675000
CY2014Q4 us-gaap Long Term Debt
LongTermDebt
8503434000
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
8415928000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
120154000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
117193000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
144161000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
155750000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
730084000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
7252300000
CY2014Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5500000000
CY2014Q2 dva Line Of Credit Facility Additional Borrowing Capacity
LineOfCreditFacilityAdditionalBorrowingCapacity
1500000000
CY2014Q2 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
3000000
CY2013Q4 dva Line Of Credit Weighted Average Interest Rate
LineOfCreditWeightedAverageInterestRate
0.0343
CY2014 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0468
CY2014Q4 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0446
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
385750000
CY2013 us-gaap Interest Expense Debt
InterestExpenseDebt
401140000
CY2012 us-gaap Interest Expense Debt
InterestExpenseDebt
270107000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
24544000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28803000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18447000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
395862000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
370920000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
344232000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2578203000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
21011000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
21277000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
21552000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
21961000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
22615000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
202245000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
310661000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
92564000
CY2014Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
218097000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
460093000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
345066000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
452085000
CY2014Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
197344000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
437536000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
484295000
CY2012 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-19630000
CY2013Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
145615000
CY2014Q3 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
17000000
CY2014 dva Agreement Period
AgreementPeriod
P5Y
CY2014Q4 us-gaap Other Commitment
OtherCommitment
1000000
CY2014 us-gaap Unrecorded Unconditional Purchase Obligation Description
UnrecordedUnconditionalPurchaseObligationDescription
Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
CY2013Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
10585172
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
53.21
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2541397
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
42.79
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
151342000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
120775000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
228698000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
310351000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
84129000
CY2014 dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
118970000
CY2013 dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
84841000
CY2012 dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
45820000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56743000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59998000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45384000
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
20351000
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
22187000
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
16874000
CY2014Q4 dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet
122574000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
73585000
CY2014 dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition
P1Y
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
59119000
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
46898000
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
88964000
CY2014 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
0
CY2013 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
0
CY2012 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
2175000
CY2014 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2013 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2011 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2014Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
358200000
CY2014 us-gaap Targeted Or Tracking Stock Corporate Events
TargetedOrTrackingStockCorporateEvents
The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.
CY2014 dva Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests
ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests
718112000
CY2013 dva Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests
ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests
628885000
CY2012 dva Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests
ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests
516387000
CY2014 us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
136000
CY2013 us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
209000
CY2014 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2013 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P14Y
CY2012 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P17Y
CY2012Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
491457000
CY2014 dva Business Combination Contingent Consideration Acquisitions Earnouts Payments
BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments
2715000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
441225000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
484179000
CY2014Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
175247000
CY2013Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
221454000
CY2013Q4 dva Business Acquisition Contingent Earn Out Fair Value Disclosure
BusinessAcquisitionContingentEarnOutFairValueDisclosure
28058000
CY2014 dva Business Combination Contingent Consideration Acquisitions
BusinessCombinationContingentConsiderationAcquisitions
18234000
CY2014 dva Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss
BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
4448000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
336588000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
377074000
CY2013Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
380020000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
270766000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
412550000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
60920000
CY2012 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
55813000
CY2014Q4 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
3328017000
CY2014Q3 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
3251824000
CY2014Q2 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
3172489000
CY2014Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
3042776000
CY2013Q4 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
3063209000
CY2013Q3 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
2999586000
CY2013Q2 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
2871673000
CY2013Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
2829582000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
522020000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
166861000
CY2014Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
354365000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
336412000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
282308000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
61642000
CY2014Q4 dva Business Acquisition Contingent Earn Out Fair Value Disclosure
BusinessAcquisitionContingentEarnOutFairValueDisclosure
39129000
CY2014 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
12887330000
CY2013 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
12160749000
CY2014 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
733490000
CY2013 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
651204000
CY2014 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
733490000
CY2013 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
651204000
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
3.45
CY2013 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
3.10
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
3.38
CY2013 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
3.03
CY2014Q4 us-gaap Variable Interest Entity Consolidated Carrying Amount Assets
VariableInterestEntityConsolidatedCarryingAmountAssets
575074000
CY2014Q4 us-gaap Variable Interest Entity Consolidated Carrying Amount Liabilities
VariableInterestEntityConsolidatedCarryingAmountLiabilities
311148000
CY2014 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
There is no single payor that accounted for more than 10% of total consolidated accounts receivable at December 31, 2014 and 2013.
CY2014 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
13012000
CY2013 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
53699000
CY2012 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
46481000
CY2012 dva Segment Reporting Information Acquisitions Related Transaction Expenses
SegmentReportingInformationAcquisitionsRelatedTransactionExpenses
30753000
CY2014 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
641330000
CY2013 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
617597000
CY2012 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
550146000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
238615000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
341426000
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
322018000
CY2014 us-gaap Interest Paid
InterestPaid
351967000
CY2013 us-gaap Interest Paid
InterestPaid
405030000
CY2012 us-gaap Interest Paid
InterestPaid
257640000
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
72389000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13236000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
208020000
CY2012 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
299517000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
184122000
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2014 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
507842000
CY2013 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
429943000
CY2013 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13236000
CY2013 dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-438007000
CY2014 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
596077000
CY2014 dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
373096000
CY2014 dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-7989000
CY2014 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-156990000
CY2013 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1016140000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
147683000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
183289000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
212278000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
136628000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
254376000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
30164000
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.98
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.87
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.70
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.87
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.01
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.65
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.21
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.08
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.87
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.87
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.01
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.21
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.96
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.85
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.68
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.85
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.99
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.64
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.18
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.08
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.68
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.99
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.64
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.18
CY2012 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-222000
CY2014Q4 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
1385707000
CY2014Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
232026000
CY2014Q4 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
9663787000
CY2013Q4 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
1040866000
CY2013Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
199841000
CY2013Q4 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
9333987000
CY2013 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-44984000
CY2012 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
459611000
CY2012 dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
-8214000
CY2012 dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
3904893000
CY2012 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-32509000
CY2014 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
272094000
CY2013 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
310394000
CY2013 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
62258000
CY2012 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
4294077000
CY2012 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
3559000

Files In Submission

Name View Source Status
0001564590-15-001035-index-headers.html Edgar Link pending
0001564590-15-001035-index.html Edgar Link pending
0001564590-15-001035.txt Edgar Link pending
0001564590-15-001035-xbrl.zip Edgar Link pending
dva-10k_20141231.htm Edgar Link pending
dva-20141231.xml Edgar Link completed
dva-20141231.xsd Edgar Link pending
dva-20141231_cal.xml Edgar Link unprocessable
dva-20141231_def.xml Edgar Link unprocessable
dva-20141231_lab.xml Edgar Link unprocessable
dva-20141231_pre.xml Edgar Link unprocessable
dva-ex121_201412317.htm Edgar Link pending
dva-ex211_201412318.htm Edgar Link pending
dva-ex231_201412319.htm Edgar Link pending
dva-ex311_2014123110.htm Edgar Link pending
dva-ex312_2014123111.htm Edgar Link pending
dva-ex321_2014123112.htm Edgar Link pending
dva-ex322_2014123113.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R104.htm Edgar Link pending
R105.htm Edgar Link pending
R106.htm Edgar Link pending
R107.htm Edgar Link pending
R108.htm Edgar Link pending
R109.htm Edgar Link pending
R11.htm Edgar Link pending
R110.htm Edgar Link pending
R111.htm Edgar Link pending
R112.htm Edgar Link pending
R113.htm Edgar Link pending
R114.htm Edgar Link pending
R115.htm Edgar Link pending
R116.htm Edgar Link pending
R117.htm Edgar Link pending
R118.htm Edgar Link pending
R119.htm Edgar Link pending
R12.htm Edgar Link pending
R120.htm Edgar Link pending
R121.htm Edgar Link pending
R122.htm Edgar Link pending
R123.htm Edgar Link pending
R124.htm Edgar Link pending
R125.htm Edgar Link pending
R126.htm Edgar Link pending
R127.htm Edgar Link pending
R128.htm Edgar Link pending
R129.htm Edgar Link pending
R13.htm Edgar Link pending
R130.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending